Teja Muralidhar Kalidindi

Mr. Teja Muralidhar Kalidindi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 August 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlexander Bolaender
Alexander Bolaender
DZDanuta Zatorska
Danuta Zatorska
HHHuazhong He
Huazhong He
SJSuhasini Joshi
Suhasini Joshi
Sahil SharmaSahil Sharma
Sahil Sharma
GCGabriela Chiosis
Gabriela Chiosis
Diseases are a manifestation of how thousands of proteins interact. In several diseases, such as cancer and Alzheimer’s disease, proteome-wide disturbances in protein-protein interactions are caused by alterations to chaperome scaffolds termed epichaperomes. Epichaperome-directed chemical probes may be useful for detecting and reversing defective chaperomes. Here we provide structural, biochemical, and functional insights into the discovery of epichaperome probes, with a focus on their use in central nervous system diseases. We demonstrate on-target activity and kinetic selectivity of a radiolabeled epichaperome probe in both cells and mice, together with a proof-of-principle in human patients in an exploratory single group assignment diagnostic study (ClinicalTrials.gov Identifier: NCT03371420). The clinical study is designed to determine the pharmacokinetic parameters and the incidence of adverse events in patients receiving a single microdose of the radiolabeled probe administered by intravenous injection. In sum, we introduce a discovery platform for brain-directed chemical probes that specifically modulate epichaperomes and provide proof-of-principle applications in their use in the detection, quantification, and modulation of the target in complex biological systems.

12 June 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
MBMesude Bicak
Mesude Bicak
KLKatharina Lückerath
Katharina Lückerath
TKTeja Muralidhar Kalidindi
Teja Muralidhar Kalidindi
MPMichael E. Phelps
Michael E. Phelps
SSSven-Erik Strand
Sven-Erik Strand
David UlmertDavid Ulmert
David Ulmert
Hu11B6 is a monoclonal antibody that internalizes in cells expressing androgen receptor (AR)-regulated prostate-specific enzyme human kallikrein-related peptidase 2 (hK2; KLK2 ). In multiple rodent models, Actinium-225–labeled hu11B6-IgG 1 ([ 225 Ac]hu11B6-IgG 1 ) has shown promising treatment efficacy. In the present study, we investigated options to enhance and optimize [ 225 Ac]hu11B6 treatment. First, we evaluated the possibility of exploiting IgG 3 , the IgG subclass with superior activation of complement and ability to mediate FC-γ-receptor binding, for immunotherapeutically enhanced hK2 targeted α-radioimmunotherapy. Second, we compared the therapeutic efficacy of a single high activity vs. fractionated activity. Finally, we used RNA sequencing to analyze the genomic signatures of prostate cancer that progressed after targeted α-therapy. [ 225 Ac]hu11B6-IgG 3 was a functionally enhanced alternative to [ 225 Ac]hu11B6-IgG 1 but offered no improvement of therapeutic efficacy. Progression-free survival was slightly increased with a single high activity compared to fractionated activity. Tumor-free animals succumbing after treatment revealed no evidence of treatment-associated toxicity. In addition to up-regulation of canonical aggressive prostate cancer genes, such as MMP7 , ETV1 , NTS , and SCHLAP1 , we also noted a significant decrease in both KLK3 (prostate-specific antigen ) and FOLH1 (prostate-specific membrane antigen) but not in AR and KLK2 , demonstrating efficacy of sequential [ 225 Ac]hu11B6 in a mouse model.

1 May 2016 in Bioorganic & Medicinal Chemistry
Verified
Journal Article
Closed access
SGSatishkumar Gadhiya
Satishkumar Gadhiya
SMSudharshan Madapa
Sudharshan Madapa
TKThomas Kurtzman
Thomas Kurtzman
IAIan L. Alberts
Ian L. Alberts
SRSteven Ramsey
Steven Ramsey
WHWayne Harding
Wayne Harding

26 July 2017 in Oncotarget
Verified
Journal Article
Open access
PDF file
DPDmitry Pankov
Dmitry Pankov
LSLudvig Sjöström
Ludvig Sjöström
TKTeja Muralidhar Kalidindi
Teja Muralidhar Kalidindi
SLSang-Gyu Lee
Sang-Gyu Lee
KSKjell Sjöström
Kjell Sjöström
David UlmertDavid Ulmert
David Ulmert
In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME) In vivo immuno-targeting of an extracellular epitope of membrane bound preferentially expressed antigen in melanoma (PRAME)

22 September 2023 in Biomedicines
Verified
Journal Article
Open access
PDF file
Sahil SharmaSahil Sharma
Sahil Sharma
SJSuhasini Joshi
Suhasini Joshi
TKTeja Muralidhar Kalidindi
Teja Muralidhar Kalidindi
CDChander Singh Digwal
Chander Singh Digwal
PPPalak Panchal
Palak Panchal
GCGabriela Chiosis
Gabriela Chiosis
Drugs with a long residence time at their target sites are often more efficacious in disease treatment. The mechanism, however, behind prolonged retention at the site of action is often difficult to understand for non-covalent agents. In this context, we focus on epichaperome agents, such as zelavespib and icapamespib, which maintain target binding for days despite rapid plasma clearance, minimal retention in non-diseased tissues, and rapid metabolism. They have shown significant therapeutic value in cancer and neurodegenerative diseases by disassembling epichaperomes, which are assemblies of tightly bound chaperones and other factors that serve as scaffolding platforms to pathologically rewire protein–protein interactions. To investigate their impact on epichaperomes in vivo, we conducted pharmacokinetic and target occupancy measurements for zelavespib and monitored epichaperome assemblies biochemically in a mouse model. Our findings provide evidence of the intricate mechanism through which zelavespib modulates epichaperomes in vivo. Initially, zelavespib becomes trapped when epichaperomes bound, a mechanism that results in epichaperome disassembly, with no change in the expression level of epichaperome constituents. We propose that the initial trapping stage of epichaperomes is a main contributing factor to the extended on-target residence time observed for this agent in clinical settings. Zelavespib’s residence time in tumors seems to be dictated by target disassembly kinetics rather than by frank drug–target unbinding kinetics. The off-rate of zelavespib from epichaperomes is, therefore, much slower than anticipated from the recorded tumor pharmacokinetic profile or as determined in vitro using diluted systems. This research sheds light on the underlying processes that make epichaperome agents effective in the treatment of certain diseases.

6 January 2023 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
CSClaire M. Storey
Claire M. Storey
Mohamed  AltaiMohamed Altai
Mohamed Altai
MBMesude Bicak
Mesude Bicak
DVDarren R. Veach
Darren R. Veach
KLKatharina Lueckerath
Katharina Lueckerath
David UlmertDavid Ulmert
David Ulmert
Noninvasive biomarkers for androgen receptor (AR) pathway activation are urgently needed to better monitor patient response to prostate cancer therapies. AR is a critical driver and mediator of resistance of prostate cancer but currently available noninvasive prostate cancer biomarkers to monitor AR activity are discordant with downstream AR pathway activity. External beam radiotherapy (EBRT) remains a common treatment for all stages of prostate cancer, and DNA damage induced by EBRT upregulates AR pathway activity to promote therapeutic resistance. [89Zr]11B6-PET is a novel modality targeting prostate-specific protein human kallikrein 2 (hK2), which is a surrogate biomarker for AR activity. Here, we studied whether [89Zr]11B6-PET can accurately assess EBRT-induced AR activity. Genetic and human prostate cancer mouse models received EBRT (2–50 Gy) and treatment response was monitored by [89Zr]11B6-PET/CT. Radiotracer uptake and expression of AR and AR target genes was quantified in resected tissue. EBRT increased AR pathway activity and [89Zr]11B6 uptake in LNCaP-AR and 22RV1 tumors. EBRT increased prostate-specific [89Zr]11B6 uptake in prostate cancer–bearing mice (Hi-Myc x Pb_KLK2) with no significant changes in uptake in healthy (Pb_KLK2) mice, and this correlated with hK2 protein levels. Implications: hK2 expression in prostate cancer tissue is a proxy of EBRT-induced AR activity that can noninvasively be detected using [89Zr]11B6-PET; further clinical evaluation of hK2-PET for monitoring response and development of resistance to EBRT in real time is warranted.